Top Markets
Coin of the day
Agile Therapeutics, Inc. Agile Therapeutics, Inc.

Agile Therapeutics, Inc.

AGRX
株式のランク #38231
Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated... Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated to the research, development, and market introduction of prescription contraception in the United States. Its flagship product is Twirla (also known by its development code, AG200-15), a combined hormonal contraceptive delivered through a patch applied once weekly. The company is also progressing with several pipeline innovations, including variations of Twirla and other new products: AG200-15 Extended Regimen (ER): A regimen designed to limit a woman to four withdrawal bleeding occurrences annually. AG200-15 smaller patch (SmP): This iteration aims for shorter, lighter withdrawal bleeds and potentially enhanced contraceptive efficacy. AG200-15 ER SmP: A combined regimen that allows for an extended contraceptive cycle while simultaneously providing fewer, lighter annual bleeding episodes. P-Patch: A contraceptive patch containing only progestin, specifically intended for women who cannot or choose not to use estrogen. Agile Therapeutics, Inc. was founded in 1997 and is based in Princeton, New Jersey.
株価
$1.51
最終同期: 2024-08-26
時価総額
$1.12M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Agile Therapeutics, Inc. (AGRX)

カテゴリー

Agile Therapeutics, Inc.(AGRX)のP/E比率
August 2026 時点のP/E比率 TTM -0.23
Agile Therapeutics, Inc. の最新の財務報告および株価によると、現在の P/E (TTM) は -0.23 です。2022 年末時点での P/E は -0.19 でした。
Agile Therapeutics, Inc. の P/E 比率の履歴(2012 〜 2026)
各年末のP/E比率
P/E比率 変化
2026 (TTM) -0.23 -22.41%
2023 -0.29 50.62%
2022 -0.19 1,145.16%
2021 -0.02 -99.65%
2020 -4.44 -33.67%
2019 -6.70 570.53%
2018 -1.00 -66.02%
2017 -2.94 -47.56%
2016 -5.61 -20.84%
2015 -7.08 62.78%
2014 -4.35 24.60%
2013 -3.49 62.42%
2012 -2.15 0.00%
類似企業や競合他社のP/E比率
P/E比率の読み方

株価収益率(P/E Ratio)は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の(0に近い)P/Eは、損失が大きいことを示します。

P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。

10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。